Bradway Robert A 4

4 · AMGEN INC · Filed May 7, 2026

AI-generated summary of this filing

Updated May 8, 2026

Amgen (AMGN) CEO Robert Bradway Receives Equity Awards (~$26.1M)

What Happened

Robert A. Bradway, Amgen's Chairman, CEO and President, received equity awards on 2026-05-05: 12,136 restricted stock units (RSUs) and 79,176 derivative awards (non-qualified stock options) associated with a grant price/reference of $329.59. The derivative portion is reported with a total value of $26,095,618. On 2026-05-06, 1,702 shares were surrendered/withheld to satisfy tax withholding obligations, valued at $329.59 per share (total ≈ $560,962).

Key Details

Transaction dates: awards granted 2026-05-05; tax withholding 2026-05-06; Form 4 filed 2026-05-07 (timely).
Award amounts: 12,136 RSUs (acquisition price $0 reported) and 79,176 derivative awards (reported value $26,095,618).
Tax withholding: 1,702 shares disposed at $329.59/share for ~$560,962 (code F — payment of exercise price or tax liability).
Footnotes: RSUs vest in four equal annual installments beginning 5/5/2027 (F1); RSUs include 1,520 Dividend Equivalents credited to unvested RSUs (F2); the derivative awards are non‑qualified stock options vesting in four equal annual installments beginning 5/5/2027 (F3).
Shares owned after the transaction: not specified in the provided filing.

Context

These were grant-type awards (A) rather than open-market purchases or sales; the withheld shares were used to meet tax obligations (common practice), not an open-market sale signaling intent. The options and RSUs vest over four years starting 5/5/2027, so economic benefit is tied to future vesting.

Form 4

Period: 2026-05-05

DirectorChairman, CEO and President

Transactions

Award
Common Stock
[F1]
2026-05-05+12,136→ 508,941 total
Tax Payment
Common Stock
[F2]
2026-05-06$329.59/sh−1,702$560,962→ 507,239 total
Award
Nqso (Right to Buy)
[F3]
2026-05-05$329.59/sh+79,176$26,095,618→ 79,176 total
Exercise: $329.59From: 2027-05-05Exp: 2036-05-05→ Common Stock (79,176 underlying)

Holdings

Footnotes (3)

[F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
[F2]These shares include 1,520 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
[F3]These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

Signature

/s/ Andrea A. Robinson, Attorney-in-Fact for Mr. Bradway|2026-05-07

1 file